摘要
免疫治療已經成為許多癌症的標準治療之一，然而，部分患者會發生中重度的免疫相關副作用，高劑量類固醇為目前建議的第一線用藥，但有少數的患者會發生類固醇抗性的免疫相關副作用。現行治療指引對此建議其他免疫抑制劑的使用，但最佳的用藥選擇目前尚無共識。本文提出一位晚期肝癌患者接受免疫治療後引起類固醇抗性的免疫性肺炎，並進展至急性呼吸窘迫症候群。經脈衝式類固醇治療後，肺炎得到完全緩解且順利脫離呼吸器出院。
參考文獻
Chen TW, Razak AR, Bedard PL, et al. A systematic review of immune-related adverse event reporting in clinical trials of immune checkpoint inhibitors. Ann Oncol 2015;26:1824-29.
Bertrand A, Kostine M, Barnetche T, et al. Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis. BMC Med 2015;13:211.
Arnaud-Coffin P, Maillet D, Gan HK, et al. A systematic review of adverse events in randomized trials assessing immune checkpoint inhibitors. Int J Cancer 2019;145:639-48.
Khunger M, Rakshit S, Pasupuleti V, et al. Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. Chest 2017;152:271-81.
Nishino M, Giobbie-Hurder A, Hatabu H, et al. Incidence of Programmed Cell Death 1 Inhibitor-Related Pneumonitis in Patients With Advanced Cancer: A Systematic Review and Meta-analysis. JAMA Oncol 2016;2:1607-16.